Net Asset Value (NAV)

£270m

(2017: £146m)

NAV PER SHARE*

£2.00

(2017: £1.52)

Gross Portfolio Value*

£175m

(2017: £54m)

£52m

Invested in Gross Portfolio

(2017: £50m)

26

Clinical trials across the portfolio

(Includes March 2019 Imara Investment)

19

Data readouts expected in 2019

£70m*

Net positive revaluation in the gross portfolio

$555m

Capital raised by portfolio companies in 2018